Skip to content
Peptide research

CNP

Also known as C-type Natriuretic Peptide
Category
Cardiovascular
Administration routes
Injectable
Regulatory status
Not FDA-approved

A natural vasodilating peptide marketed for cardiovascular and anti-aging support, though its strongest evidence is a long-acting analog's pediatric growth benefit for achondroplasia, not adult use. That effect is solid. Small human infusion experiments demonstrate vascular effects, but clinical cardiovascular benefit remains unproven. Main risks are injection-site reactions and transient blood-pressure drops. The pediatric analog is FDA-approved; native CNP is not, and unregulated products sold online carry no quality assurance.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

C-Type Natriuretic Peptide (CNP) is the third member of the natriuretic peptide family, alongside ANP and BNP. Unlike its cardiac-focused relatives, CNP is predominantly produced by vascular endothelial cells, the central nervous system, and chondrocytes (cartilage cells) in growth plates. CNP exists in two forms: CNP-22 (the 22-amino-acid active peptide) and CNP-53 (the longer pro-form). It acts through natriuretic peptide receptor B (NPR-B), activating cGMP signaling to promote vasodilation, inhibit vascular smooth muscle proliferation, and critically, stimulate endochondral bone growth.

The bone growth function of CNP proved to be its most clinically significant property. CNP is the primary regulator of endochondral ossification and acts by counteracting the growth-inhibiting effects of fibroblast growth factor receptor 3 (FGFR3) signaling. In achondroplasia, the most common form of dwarfism, a gain-of-function mutation in FGFR3 suppresses chondrocyte proliferation. CNP can override this inhibitory signal and restore more normal bone growth. This discovery led to the development of vosoritide (Voxzogo), a CNP analog that became the first-ever pharmacological treatment for achondroplasia.

Vosoritide (Voxzogo) was approved by the FDA in November 2021 for children with achondroplasia aged 5 years and older who still have open growth plates. In clinical trials, daily subcutaneous vosoritide increased annualized growth velocity by approximately 1.5-2.0 cm/year compared to placebo. Long-term extension studies have shown sustained growth benefits over 7 years. This represents a landmark in rare disease therapeutics and natriuretic peptide pharmacology.

How it works in the body

C-Type Natriuretic Peptide binds to natriuretic peptide receptor B (NPR-B) to produce cGMP. Unlike ANP/BNP, it primarily acts locally rather than systemically — promoting vasodilation in veins, stimulating endochondral bone growth through growth plate chondrocyte proliferation, and exerting anti-fibrotic and anti-hypertrophic effects on the heart.

Research overview

CNP was identified in 1990 in porcine brain by Sudoh et al. Its role in bone growth was established through knockout mouse studies showing that CNP-deficient mice had severe dwarfism, while CNP overexpression led to skeletal overgrowth. BioMarin Pharmaceutical developed vosoritide (BMN-111), a modified CNP analog resistant to enzymatic degradation, specifically for achondroplasia. The Phase 2 trial (NEJM 2019, Savarirayan et al., n=35) showed dose-dependent increases in annualized growth velocity sustained for up to 42 months. The pivotal Phase 3 trial (111-301, n=121) demonstrated a 1.57 cm/year increase in growth velocity vs placebo over 52 weeks. Long-term extension studies have confirmed sustained efficacy over 7 years. Real-world data from France, Germany, and Japan independently confirmed clinical trial findings. Additional research is exploring CNP analogs for other FGFR3-related skeletal dysplasias and vascular applications. A comprehensive 2025 review in PMC documented improvements in body proportions, craniofacial development, lumbar lordosis, and 6-minute walk distance.

Who researches CNP?

Commonly researched by

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    Not recommended for children outside an approved pediatric indication (vosoritide is approved for children with achondroplasia).

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • Injection site reactions

    High

    Savarirayan et al., Lancet 2020 — PMID 32891212; Voxzogo US prescribing information; Cureus 2025 review — PMC12352272

  • Transient hypotension (temporary blood pressure drop)

    Moderate

    Voxzogo US prescribing information (Warnings: transient decrease in blood pressure); Savarirayan et al., Lancet 2020 — PMID 32891212

  • Vomiting and gastrointestinal symptoms

    Low

    Voxzogo US prescribing information (Adverse Reactions); Savarirayan et al., Lancet 2020 — PMID 32891212; Cureus 2025 review — PMC12352272

  • Serious adverse events (rare)

    Low

    Cureus 2025 systematic review of clinical and real-world evidence — PMC12352272

Interaction summary(8)

Rated by direction with this peptide

  • Antihypertensive drugs (ACE inhibitors, ARBs, beta-blockers, calcium channel blockers)

    CautionLow

    CNP-analog dosing produces a transient blood-pressure drop within about an hour of injection, so concurrent antihypertensives could plausibly produce additive hypotension — mechanism-based, with no formal interaction study performed.

    Voxzogo US prescribing information (Warnings and Precautions: transient decrease in blood pressure)

  • Diuretics and other volume-depleting agents

    CautionLow

    Because the label mitigates post-injection hypotension by requiring adequate food and fluid intake beforehand, anything that lowers intravascular volume — loop or thiazide diuretics, or an intercurrent dehydrating illness — could amplify the transient blood-pressure drop. Inferred from labeling, not from any interaction study.

    Voxzogo US prescribing information (dosing instructions: eat and drink adequately before dosing)

  • PDE5 inhibitors (sildenafil, tadalafil)

    CautionTheoretical

    PDE5 inhibitors block cGMP breakdown while CNP raises cGMP via particulate guanylate cyclase at NPR-B, so co-exposure could theoretically potentiate vasodilation and hypotension; no clinical reports exist in the CNP literature.

    Mechanism-based (shared cGMP pathway); no interaction studies published — Voxzogo label reports no formal drug-interaction studies

  • Nitrates and nitric oxide donors

    CautionTheoretical

    Nitrates raise cGMP through soluble guanylate cyclase, a parallel arm of the same second-messenger system CNP activates via NPR-B, giving a mechanistic basis for additive vasodilation — theoretical only, and rarely co-prescribed in the pediatric population treated.

    Mechanism-based only (shared cGMP second-messenger pathway)

  • Systemic glucocorticoids (prednisone, dexamethasone)

    CautionLow

    Chronic systemic corticosteroids suppress growth-plate chondrocyte proliferation and linear growth, which opposes the endochondral growth mechanism CNP works through, so some blunting of the growth benefit is plausible during prolonged steroid courses. Glucocorticoid growth suppression itself is well established, but the combination has never been studied, so the magnitude of any blunting is inferred rather than measured.

    Established pediatric endocrinology (glucocorticoid growth suppression); mechanistic opposition at the growth plate — no dedicated co-administration study

  • Neprilysin inhibitors (sacubitril/valsartan)

    SynergisticTheoretical

    Neprilysin is a principal degradation route for endogenous CNP, so NEP inhibition raises native CNP levels; vosoritide, however, was engineered to resist NEP cleavage, so any interaction is relevant to endogenous CNP biology rather than to the therapeutic analog. Effectively neutral in the clinical setting, and the combination is essentially never encountered in the pediatric population treated.

    Natriuretic peptide clearance/neprilysin biology (Potter, FEBS J 2011) and NEP-resistance engineering of BMN 111 (Lorget et al., Am J Hum Genet 2012)

  • Recombinant growth hormone (somatropin)

    SynergisticTheoretical

    GH/IGF-1 and CNP/NPR-B act through separate growth-plate pathways and combination has been proposed as additive for skeletal dysplasia, but no controlled human trial has established safety or added benefit of co-administration.

    Mechanistic rationale only; no published RCT of vosoritide plus GH

  • CYP450-metabolized drugs generally

    NeutralLow

    CNP analogs are peptides catabolized to constituent amino acids and cleared by receptor-mediated internalization and peptidases, so classical CYP-mediated pharmacokinetic drug interactions are not expected.

    Voxzogo US prescribing information (Clinical Pharmacology: peptide catabolism; no formal drug-interaction studies conducted)

Known risks(4)

  • Injection site reactions

    Mild

    The most common adverse event in vosoritide trials, occurring in 85% of vosoritide recipients versus 82% of placebo recipients in the 52-week pivotal trial. Includes redness, swelling, itching, and pain at the injection site. Generally mild and transient.

  • Transient hypotension (temporary blood pressure drop)

    Mild to Moderate

    Blood pressure decreases have been observed, especially in younger children and infants. This is consistent with CNP's vasodilatory mechanism. Typically resolves within 1-2 hours. Monitoring recommended during early treatment.

  • Vomiting and gastrointestinal symptoms

    Mild

    Nausea and vomiting reported in clinical trials, possibly related to transient hypotensive episodes. Generally self-limiting.

  • Serious adverse events (rare)

    Rare

    In the Phase 2 trial, 4 of 35 patients (11%) experienced serious adverse events, though none were clearly attributed to vosoritide. One patient discontinued due to an adverse event.

Drug interactions(3)

  • Antihypertensive agents (ACE inhibitors, ARBs, beta-blockers)

    Vosoritide causes transient blood pressure reduction via cGMP-mediated vasodilation. Additive hypotensive effect possible with antihypertensives. Blood pressure monitoring recommended.

  • Growth hormone (somatotropin)

    Some clinicians have considered combining growth hormone with vosoritide in achondroplasia. Potential additive effects on growth velocity, but clinical data on the combination are limited. Monitor for adverse effects.

  • PDE5 inhibitors (sildenafil, tadalafil)

    Both vosoritide and PDE5 inhibitors increase cGMP levels. Theoretical risk of excessive vasodilation and hypotension with co-administration.

Research & benefits

Evidence base

Evidence Level
Strong Evidence (FDA-Approved Drug)
Total Studies
500
Human Studies
500

Vosoritide (Voxzogo) is backed by Phase 2 and Phase 3 randomized controlled trials, long-term extension studies out to 7 years, and real-world confirmation from multiple countries. The Phase 3 trial (n=121) met its primary endpoint with a statistically significant increase in growth velocity. FDA approved November 2021; EMA approved August 2021. Additional regulatory approvals in Japan, Australia, and other countries.

Researched for(6)

Rated by confidence in the evidence

  • Increased annualized growth velocity by ~1.57 cm/year in children with achondroplasia

    High

    Confirmed in a randomized, placebo-controlled phase 3 trial of 121 children over 52 weeks.

    Savarirayan et al., Lancet 2020, 'Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial' — PMID 32891212

  • Sustained growth improvement over 7 years of treatment in extension studies

    Medium

    Open-label extension studies show sustained growth benefit through 7 years, without a randomized comparator.

    Jones et al., Cureus 2025, 'Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence' (systematic review; documents sustained benefit over seven years) — PMC12352272

  • Improved body proportions (upper-to-lower segment ratio) with continued treatment

    Medium

    Extension studies report improved body proportions versus historical controls, not a randomized comparison.

    Jones et al., Cureus 2025 systematic review (reports improvements in skeletal proportions and body alignment) — PMC12352272

  • Reduction in lumbar lordosis and leg bowing in real-world cohorts

    Medium

    Leg bowing improved in randomized trials; lordosis improvement rests on smaller observational cohorts.

    Effect of vosoritide on genu varum in children with achondroplasia after 1 year in randomized placebo-controlled trials, J Endocr Soc 2026;10(3):bvag024 — PMID 41766933. Lordosis data: Cureus 2025 review — PMC12352272. Specific effect sizes (~3.4 degrees mechanical axis, ~5.2 degrees lordosis) are unconfirmed.

  • Counteracts FGFR3 overactivation — addresses the root cause of achondroplasia

    Low

    Well-described mechanism in animal and chondrocyte models, not yet directly confirmed in human patients.

    Yasoda et al., Nat Med 2004 (CNP overexpression rescues achondroplasia in mice via MAPK-dependent pathway) and Lorget et al., Am J Hum Genet 2012 (BMN 111 in Fgfr3ach mice)

  • Potential cardiovascular benefits via vasodilation and anti-proliferative effects on vascular smooth muscle

    Low

    Mechanistic and animal findings are supplemented by small human vascular infusion experiments; clinical cardiovascular benefit remains unproven.

    Moyes AJ, Hobbs AJ. C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int J Mol Sci. 2019;20(9):2281. PMID 31072047.

Benefits(6)

  • Increased annualized growth velocity by ~1.57 cm/year in children with achondroplasia

    Phase 3 111-301 trial (PMID 32891212, Lancet 2020, n=121)

  • Sustained growth improvement over 7 years of treatment in extension studies

    Long-term extension data (BioMarin, multiple conference presentations 2023-2025)

  • Improved body proportions (upper-to-lower segment ratio) with continued treatment

    Jones et al., Cureus review 2025 (PMC12352272)

  • Reduction in lumbar lordosis and leg bowing in real-world cohorts

    Retrospective studies from France, Germany, Japan (2024-2025)

  • Counteracts FGFR3 overactivation — addresses the root cause of achondroplasia

    Yasoda et al., Nature Med 2004; Lorget et al., Am J Hum Genet 2012

  • Potential cardiovascular benefits via vasodilation and anti-proliferative effects on vascular smooth muscle

    Multiple preclinical studies on CNP vascular biology

Key studies(3)

  1. Savarirayan R, Irving M, Bacino CA, et al.

    New England Journal of Medicine

    2019

    Vosoritide at 15 mcg/kg/day produced a sustained dose-dependent increase in annualized growth velocity in children aged 5-14 with achondroplasia. Growth velocity remained elevated for up to 42 months. Adverse events included injection site reactions and transient hypotension.

  2. Savarirayan R, Tofts L, Irving M, et al.

    The Lancet

    2020

    Vosoritide 15 mcg/kg/day increased annualized growth velocity by 1.57 cm/year compared to placebo (p<0.0001). 70% of vosoritide-treated children vs 28% of placebo had at least 50% increase in growth velocity. Well tolerated; injection site reactions most common adverse event.

  3. Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence

    Systematic ReviewMultiple studies reviewedUp to 7 years follow-up

    Multiple authors

    PMC Review

    2025

    Comprehensive review confirming sustained growth velocity increases of 1.5-2.0 cm/year, improvements in body proportions, craniofacial development, lumbar lordosis, and leg bowing. Real-world data from France, Germany, and Japan independently confirmed trial results. Common adverse effects: mild injection site reactions and transient hypotension in infants.

Regulation & availability

Why researchers look at it

CNP analogs like vosoritide represent a groundbreaking advance in rare disease therapeutics — the first-ever drug to address the underlying cause of achondroplasia and promote bone growth in affected children. With FDA and EMA approval, strong long-term data, and real-world confirmation, vosoritide has changed the treatment paradigm for the most common form of skeletal dysplasia.

Estimated cost
Not available as a consumer product — vosoritide (Voxzogo) is prescription only for achondroplasia (~$300K/yr)
FDA status
Native CNP is not FDA-approved. Vosoritide (Voxzogo), a CNP analog, received accelerated approval on November 19, 2021, initially for children aged five and older with achondroplasia and open epiphyses. FDA expanded the indication on October 20, 2023, to include younger pediatric patients. EU authorization was granted August 26, 2021; the current EU minimum age is four months. Vosoritide also has approvals in Japan and Australia.
WADA status
Not Explicitly Listed. Vosoritide is a growth-modulating peptide that could theoretically fall under WADA's S2 category (Peptide Hormones, Growth Factors). However, it specifically stimulates bone growth plate activity rather than muscle-building GH pathways. Athletes with achondroplasia requiring vosoritide may apply for a Therapeutic Use Exemption (TUE). Not commonly associated with doping or performance enhancement.
Prescribability
Native CNP is not an FDA-approved medication. Its analog vosoritide (Voxzogo) is approved to increase linear growth in pediatric patients with achondroplasia and open growth plates, including children under five.
Availability
Vosoritide (Voxzogo), manufactured by BioMarin, is a prescription CNP analog for pediatric achondroplasia with open growth plates, including children under five in the US. It is approved in the US, EU, Japan, Australia and other countries. Another CNP analog, navepegritide (Yuviwel), was FDA-approved in February 2026 for patients aged two and older with achondroplasia and open growth plates. These approvals do not cover native CNP.

International status

  • EU

    EMA-approved (Voxzogo) Aug 2021

  • US

    Native CNP is not FDA-approved; its analog vosoritide (Voxzogo) was FDA-approved in November 2021 for achondroplasia.

  • Worldwide

    Approved in US, EU, Japan, others (as Voxzogo for achondroplasia only)

Regulatory timeline(10)

  1. 1990
    CNP identified in porcine brain by Sudoh et al.
  2. 2004
    Yasoda et al. demonstrate CNP counteracts FGFR3 signaling in bone growth (Nature Med)
  3. 2012
    Lorget et al. show BMN-111 (vosoritide) rescues achondroplasia phenotype in mice
  4. 2014-01-13
    The Phase 2 vosoritide study began recruitment.
  5. 2019
    Phase 2 results published in NEJM showing sustained growth velocity increase
  6. 2020
    Phase 3 111-301 trial results published in Lancet — primary endpoint met
  7. 2021-08
    EMA approves vosoritide (Voxzogo) for achondroplasia in children aged 2+
  8. 2021-11
    FDA approves vosoritide (Voxzogo) for achondroplasia in children aged 5+
  9. 2022
    Vosoritide approved in Japan; long-term extension data presented at conferences
  10. 2025
    Comprehensive review confirms sustained 7-year efficacy; real-world data from multiple countries

Sources & FAQs

Research sources(6)

Frequently asked questions(4)

What is the difference between CNP and ANP/BNP?

While ANP and BNP are primarily cardiac hormones involved in blood pressure and fluid regulation, CNP is predominantly produced in blood vessels, brain, and cartilage growth plates. CNP's most clinically significant function is stimulating bone growth, which led to the development of vosoritide for achondroplasia. CNP signals through a different receptor (NPR-B) than ANP/BNP (NPR-A).

How does vosoritide work for achondroplasia?

Achondroplasia is caused by an overactive FGFR3 receptor that suppresses bone growth in the growth plates. Vosoritide (a CNP analog) counteracts this FGFR3 overactivation by stimulating the NPR-B/cGMP pathway in chondrocytes, restoring more normal endochondral ossification and increasing linear bone growth.

Can adults with achondroplasia benefit from vosoritide?

Vosoritide works by stimulating growth plate cartilage, so it is only effective while the growth plates (epiphyses) are still open. Once growth plates close (typically in late adolescence), vosoritide cannot increase height. The drug is approved for children with open growth plates.

What are the main side effects of vosoritide?

The most common side effects are injection site reactions (redness, swelling, pain) occurring in 85% of vosoritide recipients versus 82% of placebo recipients in the pivotal 52-week trial, and transient hypotension (temporary drop in blood pressure) especially in younger children. These are generally mild and manageable. Vomiting and headache have also been reported.